

13 Nov 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: US approval for Lilly's obesity drug; a look at the future of the obesity market; BMS's ADC deal; Roche's MS plans; and one Chinese firm's CAR-T plans.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 10 November 2023, including: US approval for [*Eli Lilly and Company*](#)'s obesity drug; a look at the future of the obesity market; [*Bristol Myers Squibb Company*](#)'s ADC deal; [*Roche Holding AG*](#)'s MS plans; and one Chinese firm's CAR-T plans.

This and all our other podcasts are available on the *Citeline* channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*Lilly Plans 'Big, Bold' Launch For Zepbound*](#)" - Scrip, 8 Nov, 2023.)

(Also see "[*The Next Frontier In Obesity: Better, Not More, Weight Loss*](#)" - Scrip, 6 Nov, 2023.)

(Also see "[*BMS Spends \\$100m On Orum's Antibody-Guided Protein Degradar*](#)" - Scrip, 7 Nov, 2023.)

(Also see "[*How Roche Plans To Stay Ahead In MS And Catch Up In Alzheimer's*](#)" - Scrip, 3 Nov, 2023.)

(Also see "[*China CEO Interview: Gracell Aims To Enter US CAR-T Sector Through Partnerships*](#),"

Faster Delivery" - Scrip, 6 Nov, 2023.)

Click here to explore this interactive content online ✨